Eupraxia Pharmaceuticals (EPRX)
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical ne...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
- 52wk Low
- --
- Float Mkt Cap
- --
- Market Cap
- --
- P/ETTM
- --
- P/EDynamic
- --
- P/EStatic
- --
- EPSTTM
- --
- EPSDynamic
- --
- EPSStatic
- --
- BVPS
- --
- P/B
- --
- Circulating Supply
- --
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- --
- Min lot size
- --
- Currency
- --
Eupraxia Pharmaceuticals Analyst Rating
View moreForecast & Rating
Sep 24, 2026Price forecast
$16.3596.87%
Forecast & RatingStrong buy
12analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 32 minutes ago
Eupraxia says EP-104GI keeps 64% of EoE patients in remission at 52 weeks in RESOLVE trial data
- Market Beat · Sep 24 at 12:42 PM
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Wedbush
- Market Beat · Sep 15 at 05:00 PM
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Gap Down - Here's What Happened
- PUBT · Sep 8 at 12:05 PM
Eupraxia Pharmaceuticals begins trading on Nasdaq Global Select Market after uplisting from Nasdaq Capital Market
